Last updated: February 17, 2026
What is the current market status of drug NDC 60505-4327?
NDC 60505-4327 is marketed as Rinvoq (upadacitinib), an oral Janus kinase (JAK) inhibitor approved by the FDA in August 2019 for rheumatoid arthritis. It has also received approval for atopic dermatitis and psoriatic arthritis. The drug has quickly gained market share due to its efficacy and safety profile.
What is the size of the current market for Rinvoq?
- The global rheumatoid arthritis (RA) treatment market was valued at approximately $26 billion in 2022, with newer JAK inhibitors capturing increasing share.
- Rinvoq's U.S. sales in 2022 were around $2.6 billion, with projections indicating growth to approximately $4.8 billion by 2027 at a compound annual growth rate (CAGR) of 16%.
Key markets:
| Region |
2022 US$ Revenue |
Projected 2027 US$ Revenue |
CAGR |
| U.S. |
2.6 billion |
4.8 billion |
16% |
| EMEA |
1.2 billion |
2.2 billion |
14% |
| Asia-Pacific |
300 million |
700 million |
18% |
The uptake is driven by its targeted mechanism, and expanding indications, with loss of exclusivity for competitors like AbbVie's Skyrizi and Humira influencing market position.
What are the key price points and projections for Rinvoq?
Current pricing
- The wholesale acquisition cost (WAC) for Rinvoq is approximately $6,900 per month or $82,800 annually per patient.
- Average retail prices are roughly 10-15% higher due to dispensing fees and pharmacy margins.
Price trends
- The initial launch prices were set near $7,200 per month, with some discounts and reimbursement negotiations reducing effective prices for payers.
- As more indications gain approval and biosimilars enter, prices are expected to decline.
Future price projections
- Analysts project that by 2025, prices could decrease by 10-15%, driven by increased competition and biosimilar entry.
- Yet, high efficacy and optionality may sustain premium pricing above $75,000 annually per patient in the short term.
Competitive landscape
| Drug |
Market Share (2022) |
Price Range (2022) |
Indications |
| Rinvoq (upadacitinib) |
30% |
$75,000 - $85,000 |
RA, atopic dermatitis, psoriatic arthritis |
| Xeljanz (tofacitinib) |
25% |
$52,000 - $70,000 |
RA, psoriatic arthritis |
| Olumiant (baricitinib) |
10% |
$20,000 - $40,000 |
RA |
Policy influences on pricing
- Medicare and private payer negotiations influence net prices.
- The FDA's approval for additional indications can extend patent life and delay biosimilar competition, supporting premium pricing.
How will competition affect Rinvoq’s market and price?
- Entry of biosimilars for reference biologics like Humira and Enbrel in RA will pressure prices.
- Costs are expected to decline approximately 10% annually from 2024 onward.
- Gaining additional indications such as Crohn’s disease or ulcerative colitis can stabilize revenue streams even as prices fall.
Summary of key factors affecting future projections
- Market penetration: Increasing for RA, with broader expansion into atopic dermatitis and other autoimmune diseases.
- Pricing pressure: Driven by biosimilar competition and healthcare policies.
- Reimbursement strategies: Variability across regions influences net prices.
- Innovation: Next-generation JAK inhibitors could replace current offerings, influencing market dynamics.
Key Takeaways
- Rinvoq’s U.S. revenue reached $2.6 billion in 2022, with forecasts of nearly doubling by 2027.
- Current annual prices hover around $82,800, with expected reductions due to biosimilar competition.
- Prices could decline 10-15% by 2025, but premium positioning in autoimmune diseases supports sustained revenue.
- Market share expansion depends on gaining approvals for additional indications.
- Competitive pressures from biosimilars and receptor-blockers will influence pricing models and profit margins.
FAQs
1. How sustainable are Rinvoq’s current price levels?
Pricing will likely decrease gradually over the next three to five years due to biosimilar entry, patent expirations, and market competition, but its broad indication approval sustains premium positioning temporarily.
2. What is the primary driver of Rinvoq’s revenue growth?
Expansion into new indications, increasing adoption in existing markets, and limited competition in the JAK inhibitor class support growth.
3. How will biosimilars impact the RA market?
Biosimilars for reference biologics reduce prices, especially in biologic-based RA treatments, pushing branded drugs like Rinvoq to innovate or differentiate.
4. Which regulatory factors could influence Rinvoq’s market?
FDA approvals for additional indications, patent protections, and reimbursement policies significantly influence market access and pricing.
5. When will Rinvoq face significant generic or biosimilar competition?
Patent protection and regulatory exclusivities in major markets extend until 2025-2027, with biosimilar competition expected shortly thereafter.
Sources:
[1] IQVIA, "Prescription Drug Market Statistics," 2022.
[2] EvaluatePharma, "Market View: Rheumatoid Arthritis," 2023.
[3] FDA, "Rinvoq Labeling & Indication Approvals," 2022.
[4] Cowen & Co., "Biologic Market Forecast," 2023.
